QNRX
Quoin Pharmaceuticals, Ltd.
Key Financials
Net Income
$-15804655
↓ 76.3%
Total Liabilities
$7.3M
↑ 11.8%
Cash & Equivalents
$3.8M
↑ 5.4%
Shareholders' Equity
$13.1M
↑ 42.5%
Operating Cash Flow
$-13540994.00
↓ 72.3%
Total Assets
$20.4M
↑ 29.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/4/2026 | View on SEC |
| SCHEDULE 13G | 6/2/2026 | View on SEC |
| 424B3 | 6/2/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| SCHEDULE 13G/A | 4/29/2026 | View on SEC |
| 4 | 3/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | QNRX |
| Company Name | Quoin Pharmaceuticals, Ltd. |
| CIK | 1671502 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| State of Incorporation | L3 |
| Phone | 97299741444 |